Replimune Group, Inc. last reported quarterly results on Oct 28, 2026, for Q2 FY2027 (the quarter ended Sep 30, 2026): diluted EPS of -$0.54. It usually reports 28–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 2, 2027.
Results for Q3 FY2027, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 3, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q2 FY2027
ended Sep 30, 2026
|
—
|
-57
+31.3%
|
-0.54
+40.0%
|
|
Aug 14, 2026
45 days after quarter end
|
Q1 FY2027
ended Jun 30, 2026
|
—
|
-70
+19.5%
|
-0.72
+24.2%
|
|
Feb 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Dec 31, 2025
|
—
|
-71
-6.9%
|
-0.77
+2.5%
|
|
Nov 6, 2025
37 days after quarter end
|
Q2 FY2026
ended Sep 30, 2025
|
—
|
-83
-56.6%
|
-0.90
-32.4%
|
|
Aug 7, 2025
38 days after quarter end
|
Q1 FY2026
ended Jun 30, 2025
|
—
|
-87
-61.2%
|
-0.95
-21.8%
|
|
May 22, 2025
52 days after quarter end
|
Q4 FY2025
ended Mar 31, 2025
|
—
|
-74
-34.6%
|
-0.81
+1.4%
|
|
Feb 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Dec 31, 2024
|
—
|
-66
-29.8%
|
-0.79
-2.6%
|
|
Nov 12, 2024
43 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- REPL (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737953
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.